
Prostate Cancer
Latest News

Video Series

Latest Videos
Shorts









CME Content
More News

Alicia Morgans, MD, MPH, discusses the background of the ARACOG trial in prostate cancer.

Brian Myre, MD, discusses early data with SYNC-T SV-102 in advanced/metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

Fred Saad, MD, CQ, FRCS, FCAHS, discusses data from subgroup analyses of the PSMAddition trial by disease volume and in de novo/recurrent mHSPC.

The FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic androgen pathway modulation–naive or sensitive prostate cancer.

FDA approved generic gallium Ga 68 gozetotide injection for PET imaging of PSMA-positive lesions in prostate cancer.

ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.

Aglatimagene besadenovec plus ERBT displayed an accumulating benefit in high-risk prostate cancer after extended follow-up.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Long-term follow-up data showed ePLND significantly reduces the risk of metastasis in ISUP GG 3-5 prostate cancer with radical prostatectomy.

TALAPRO-3 showed talazoparib plus enzalutamide cut progression or death risk by 52% in HRR-altered mCSPC vs enzalutamide alone.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

OncLive spoke with experts in the field of GU oncology to gain their insights on the most notable presentations from the 2026 AUA Annual Meeting.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Dr Polascik on an AI-Driven Urine Volatile Compound Profiling Approach for Prostate Cancer Detection
Thomas J. Polascik, MD, discusses findings from a study of an AI-based VOC assay for prostate cancer detection.

Enzalutamide plus radium-223 demonstrated no early survival advantage but an 80% death risk reduction for long-term survivors in mCRPC at over 60 months.

Rucaparib showed a manageable and consistent safety profile in patients with BRCA-mutated prostate cancer.

No new safety signals were identified, and imAEs were predominantly low-grade and consistent with the known durvalumab safety profile.

Adding lutetium Lu 177 vipivotide tetraxetan to ADT and ARPI deepened PSA responses and reduced the risk of PSA progression by 58% in patients with mHSPC.

Talazoparib plus enzalutamide data show rPFS correlates moderate-to-strongly with OS in first-line mCRPC across biomarker-defined subgroups.

Enzalutamide plus leuprolide produced a median treatment suspension of 17 months vs 11.5 months with leuprolide alone in biochemically recurrent prostate cancer.

































































